A detailed history of Pacer Advisors, Inc. transactions in Argenx Se stock. As of the latest transaction made, Pacer Advisors, Inc. holds 789 shares of ARGX stock, worth $504,833. This represents 0.0% of its overall portfolio holdings.

Number of Shares
789
Previous 832 5.17%
Holding current value
$504,833
Previous $451,000 7.54%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 22, 2025

SELL
$520.52 - $638.33 $22,382 - $27,448
-43 Reduced 5.17%
789 $485,000
Q3 2024

Nov 12, 2024

SELL
$434.22 - $551.9 $19,105 - $24,283
-44 Reduced 5.02%
832 $451,000
Q2 2024

Aug 13, 2024

SELL
$356.01 - $451.55 $28,480 - $36,124
-80 Reduced 8.37%
876 $376,000
Q1 2024

May 10, 2024

SELL
$356.95 - $413.29 $25,700 - $29,756
-72 Reduced 7.0%
956 $376,000
Q4 2023

Jan 16, 2024

BUY
$338.91 - $506.01 $1,016 - $1,518
3 Added 0.29%
1,028 $391,000
Q3 2023

Nov 13, 2023

BUY
$369.35 - $548.43 $39,151 - $58,133
106 Added 11.53%
1,025 $503,000
Q2 2023

Jul 12, 2023

BUY
$360.14 - $422.58 $17,286 - $20,283
48 Added 5.51%
919 $358,000
Q1 2023

May 02, 2023

BUY
$334.23 - $403.65 $1,002 - $1,210
3 Added 0.35%
871 $324,000
Q4 2022

Feb 06, 2023

BUY
$342.17 - $402.31 $297,003 - $349,205
868 New
868 $328,000
Q1 2022

Apr 05, 2022

SELL
$254.45 - $351.06 $106,869 - $147,445
-420 Closed
0 $0
Q4 2021

Feb 03, 2022

SELL
$272.01 - $353.03 $8,160 - $10,590
-30 Reduced 6.67%
420 $147,000
Q3 2021

Oct 15, 2021

SELL
$295.0 - $350.58 $15,635 - $18,580
-53 Reduced 10.54%
450 $136,000
Q1 2021

Apr 05, 2021

SELL
$268.3 - $380.31 $7,244 - $10,268
-27 Reduced 5.09%
503 $139,000
Q4 2020

Jan 20, 2021

BUY
$248.13 - $308.36 $131,508 - $163,430
530 New
530 $156,000
Q4 2019

Feb 10, 2020

SELL
$106.59 - $164.21 $120,020 - $184,900
-1,126 Closed
0 $0
Q3 2019

Oct 10, 2019

BUY
$113.31 - $150.51 $127,587 - $169,474
1,126 New
1,126 $128,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $35.4B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Pacer Advisors, Inc. Portfolio

Follow Pacer Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pacer Advisors, Inc. with notifications on news.